It’s time to approach cancer biology from a new perspective.
Precision medicine has revolutionized the treatment of certain cancers; however, most targeted therapies have short-lived benefits due to the rapid emergence of resistance mutations.
Delphia’s activation lethality platform offers the potential for new cancer medicines that are effective on their own while also combating the emergence of resistance to classic targeted therapies.
We are bold, courageous, big-picture thinkers.
With a shared sense of purpose and urgency, our distinguished team brings a significant track record of progressing new cancer medicines from discovery through clinical development, regulatory approval and commercialization.
Join Our Team
Delphia is a fast-growing company looking for talented individuals to join our team.
Together, we aim to reimagine the function of cancer medicines and establish activation lethality as the next wave of oncology therapeutics.
